Microbiology Department, Donostia University Hospital-Biodonostia Health Research Institute, San Sebastián, Spain.
Biomedical Research Center Network for Respiratory Diseases (CIBERES), San Sebastián, Spain.
Eur J Clin Invest. 2019 Aug;49(8):e13150. doi: 10.1111/eci.13150. Epub 2019 Jul 1.
Helicobacter pylori infection is associated with chronic gastritis, ulcers and gastric cancer. Antimicrobial resistance has increased worldwide affecting the efficacy of current treatments. Most guidelines recommend implementation of regional surveillance of primary antibiotic resistance of H pylori. Only a fraction of individuals infected with H pylori develop gastric diseases which are related to virulence factors of the bacteria. The aims of the study were to determine the primary antimicrobial resistance rates of H pylori and to know the virulence factors prevalence of strains circulating in Southern Europe.
Susceptibility testing by Etest to clarithromycin, levofloxacin, metronidazole, amoxicillin and tetracycline was performed in 102 isolates (99 naïve patients). The prevalence of virulence factors (cagA, vacA, oipA, babA and dupA) was evaluated in 102 H pylori isolates from patients with mild-disease symptoms and in 22 isolates from patients with severe-disease symptoms.
Primary resistance rates were 12.1% to clarithromycin, 13.1% to levofloxacin, 24.2% to metronidazole and 0% to amoxicillin and tetracycline. Combined resistance to clarithromycin and levofloxacin was 3% and to clarithromycin and metronidazole 4%. Prevalence of virulence factors in the mild- and severe-disease group was 35.3% and 81.8% for cagA, 20.6% and 54.5% for cagA/vacAs1m1, 94.1% and 95.4% for babA2, 78.4% and 100% for oipA and 30.4% and 18.2% for dupA.
Primary antimicrobial resistance rates were under 15% for clarithromycin and levofloxacin. The prevalence of H pylori carrying the virulent genotype cagA/vacAs1m1 was higher than 20% in the mild-disease and 54% in the severe-disease symptom group.
幽门螺杆菌感染与慢性胃炎、溃疡和胃癌有关。抗生素耐药性在全球范围内的增加影响了当前治疗的效果。大多数指南建议实施幽门螺杆菌主要抗生素耐药性的区域性监测。只有一小部分感染幽门螺杆菌的人会发展为与细菌毒力因子相关的胃部疾病。本研究的目的是确定幽门螺杆菌的主要抗生素耐药率,并了解在南欧流行的菌株的毒力因子流行率。
对 102 株(99 例初治患者)分离株进行 Etest 法克拉霉素、左氧氟沙星、甲硝唑、阿莫西林和四环素药敏试验。在 102 例症状较轻的患者和 22 例症状较重的患者的幽门螺杆菌分离株中,评估了毒力因子(cagA、vacA、oipA、babA 和 dupA)的流行率。
克拉霉素、左氧氟沙星、甲硝唑和阿莫西林的原发耐药率分别为 12.1%、13.1%、24.2%和 0%。克拉霉素和左氧氟沙星联合耐药率为 3%,克拉霉素和甲硝唑联合耐药率为 4%。轻症和重症组 cagA 的流行率分别为 35.3%和 81.8%,cagA/vacAs1m1 分别为 20.6%和 54.5%,babA2 分别为 94.1%和 95.4%,oipA 分别为 78.4%和 100%,dupA 分别为 30.4%和 18.2%。
克拉霉素和左氧氟沙星的主要抗生素耐药率低于 15%。携带毒力基因型 cagA/vacAs1m1 的幽门螺杆菌在轻症和重症症状组的流行率分别高于 20%和 54%。